TNFRSF1A polymorphisms and MS
Statistical signals transform into pathogenetic mechanisms
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
A genetic contribution to multiple sclerosis (MS) risk is now well-established, the strongest contributor being human leukocyte antigen (HLA). The quest for non-HLA MS susceptibility genes has reached a new level during the past 5 years through the application of genome-wide association studies. International consortia have designed studies with adequate power to identify susceptibility loci with substantially weaker effects than HLA. More than 50 such loci were recently confirmed or suggested in a large international analysis of 9,772 patients with MS and 17,376 controls.1 A strikingly high proportion of the identified loci code for immune system components, in particular cytokine pathways, costimulation, and signal transduction, many of these linked with T-cell activation and T-helper-cell differentiation.
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 2010
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosisManuel Comabella, Ana B. Caminero, Sunny Malhotra et al.Neurology, April 26, 2013 -
Editorial
TNFRSF1A in multiple sclerosisA tale of soluble receptors and signaling cascadesPentti J. Tienari, Reinhard Hohlfeld et al.Neurology, October 30, 2013 -
Null Hypothesis
Tumor Necrosis Factor Inhibition and Parkinson DiseaseA Mendelian Randomization StudyXiaoying Kang, Alexander Ploner, Nancy L. Pedersen et al.Neurology, February 19, 2021 -
Article
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locusLinda Ottoboni, Irene Y. Frohlich, Michelle Lee et al.Neurology, October 30, 2013


